MiSeqDx NGS Sequencer, Illumina (CAT#: STEM-GTPO-0055-ZJF)

The MiSeqDx NGS Sequencer is manufactured by Illumina.
The MiSeqDx instrument is the first Food and Drug Administration-cleared in vitro diagnostic & next-generation sequencing (NGS) system. Illumina also received Food and Drug Administration premarket clearance for the MiSeqDx Cystic Fibrosis 139-Variant Assay, MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and MiSeqDx Universal Kit.

Condition: Certified pre-owned
Maximum Read Length: Up to 2 × 300 bp
Output (2 x 150 bp run): ≥ 5 Gb
Reads passing filters (2 x 150 bp run): ≥ 15 million
Accuracy-Germline: >99.9% Overall Percent Agreement to Reference Results
Accuracy-Somatic: 100% Overall Percent Agreement to Reference Results
Reproducibility-Germline: 99.88% Overall Percent Agreement to Reference Results
Reproducibility-Somatic: 99.6% Percent Expected Call for mutant samples
Q30 score (at read length of 2 × 150 bp): ≥ 80%
Power Requirements: 100–240V AC at 50/60Hz, 10A, 400W
RFID Radio Frequency: 13.56 MHz
RFID Power: 100 mW
Samples per Run: Depending on assay
LED: 520, 660 nm
Warranty: 90-day warranty (US and Canada ONLY)

Food and Drug Administration-Regulated and CE-IVD-Marked NGS System
A Growing IVD Menu
Simple NGS Workflow
User-Friendly, Intuitive Software

Illumina NextSeq 1000 NGS Sequencer, Illumina
MiSeqDx NGS Sequencer, Illumina
NexSeq 550 NGS Sequencer, Illumina